22 February 2016 - Trevena today announced that the U.S. FDA has granted Breakthrough Therapy designation to the Company's lead product candidate, intravenous oliceridine (TRV130), for the management of moderate-to-severe acute pain.

For more details, go to: http://www.trevenainc.com/news-details.php?id=135